Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 3/20 | 0.45 |
| ▸ | MC5R | P33032 | 2/20 | 0.45 |
| ▸ | CPS1 | P31327 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FPR1 | P21462 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12536947 | 0.84 | MC4R (0.56) | MC4RMC5R | |
| SCHEMBL15382425 | 0.84 | MC4R (0.56) | MC4RMC5R | |
| SCHEMBL1920425 | 0.84 | MC4R (0.60) | KMT2AMC4RMC5RMEN1 | |
| SCHEMBL1920280 | 0.84 | MC4R (0.60) | KMT2AMC4RMC5RMEN1 | |
| SCHEMBL2133690 | 0.82 | FFAR1 (0.47) | KMT2ACPS1FPR1FPR2 | |
| SCHEMBL14480439 | 0.82 | FFAR1 (0.47) | KMT2ACPS1FPR1FPR2 | |
| SCHEMBL10289079 | 0.82 | FFAR1 (0.47) | KMT2ACPS1FPR1FPR2 | |
| SCHEMBL10288350 | 0.82 | FFAR1 (0.47) | KMT2ACPS1FPR1FPR2 | |
| SCHEMBL2762178 | 0.82 | KDM1A (0.50) | KMT2AMC4RMC5RMEN1 | |
| SCHEMBL12536942 | 0.81 | DRD2 (0.54) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| EP-2326638-A1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | Pfizer Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | KMT2A 1449/4885ALDH1A1 2242/4885GAA 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.